Cargando…

Soluble Amyloid-beta Aggregates from Human Alzheimer’s Disease Brains

Soluble amyloid-beta (Aβ) aggregates likely contribute substantially to the dementia that characterizes Alzheimer’s disease. However, despite intensive study of in vitro preparations and animal models, little is known about the characteristics of soluble Aβ aggregates in the human Alzheimer’s diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esparza, Thomas J., Wildburger, Norelle C., Jiang, Hao, Gangolli, Mihika, Cairns, Nigel J., Bateman, Randall J., Brody, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137165/ https://www.ncbi.nlm.nih.gov/pubmed/27917876 http://dx.doi.org/10.1038/srep38187

Ejemplares similares

Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls
por: Esparza, Thomas J., et al.
Publicado: (2018)

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
por: Brody, David L., et al.
Publicado: (2017)

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
por: Wildburger, Norelle C., et al.
Publicado: (2017)

Amyloid-β Plaques in Clinical Alzheimer’s Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity
por: Wildburger, Norelle C., et al.
Publicado: (2018)

Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer’s disease
por: Sideris, Dimitrios I, et al.
Publicado: (2021)

A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice
por: Rofo, Fadi, et al.
Publicado: (2022)

Effect of Bacterial Amyloid Protein Phenol−Soluble Modulin Alpha 3 on the Aggregation of Amyloid Beta Protein Associated with Alzheimer’s Disease
por: Peng, Bushu, et al.
Publicado: (2023)

Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer’s related amyloid-beta pathology
por: Su, Shiran, et al.
Publicado: (2022)

A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer’s disease brain
por: Stern, Andrew M, et al.
Publicado: (2022)

Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
por: Povala, Guilherme, et al.
Publicado: (2021)

Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer’s disease mouse model
por: Freitag, Kiara, et al.
Publicado: (2022)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

Minimal Long-Term Neurobehavioral Impairments after Endovascular Perforation Subarachnoid Hemorrhage in Mice
por: Fanizzi, Claudia, et al.
Publicado: (2017)

Oxidation of Methionine-35 in Alzheimer’s amyloid-beta peptide and the aggregation of the oxidized peptide
por: Friedemann, Merlin, et al.
Publicado: (2015)

Polyphenols Modulate Alzheimer’s Amyloid Beta Aggregation in a Structure-Dependent Manner
por: Phan, Huong T. T., et al.
Publicado: (2019)

Amyloid-beta aggregation implicates multiple pathways in Alzheimer’s disease: Understanding the mechanisms
por: Iliyasu, Musa O., et al.
Publicado: (2023)

Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
por: Bateman, David A, et al.
Publicado: (2007)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

Familial Alzheimer’s Disease-Related Mutations Differentially Alter Stability of Amyloid-Beta Aggregates
por: Rezaei-Ghaleh, Nasrollah, et al.
Publicado: (2023)

Screening for Novel Inhibitors of Amyloid Beta Aggregation and Toxicity as Potential Drugs for Alzheimer’s Disease
por: Sharari, Sanaa, et al.
Publicado: (2023)

Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase
por: Wildburger, Norelle C., et al.
Publicado: (2012)

Oxidation destabilizes toxic amyloid beta peptide aggregation
por: Razzokov, J., et al.
Publicado: (2019)

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
por: Rofo, Fadi, et al.
Publicado: (2021)

Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain
por: Gil-Bea, Francisco, et al.
Publicado: (2012)

Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
por: Sepkhanova, I., et al.
Publicado: (2009)

Brain Cells Release Calreticulin That Attracts and Activates Microglia, and Inhibits Amyloid Beta Aggregation and Neurotoxicity
por: Reid, Kyle M., et al.
Publicado: (2022)

Allium roseum L. extract inhibits amyloid beta aggregation and toxicity involved in Alzheimer’s disease
por: Boubakri, Abdelbasset, et al.
Publicado: (2020)

Crocus-derived compounds alter the aggregation pathway of Alzheimer’s Disease: associated beta amyloid protein
por: Koulakiotis, Nikolaos Stavros, et al.
Publicado: (2020)

Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease
por: Wen, Ya-Ru, et al.
Publicado: (2018)

Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer’s disease: a stochastic modelling approach
por: Proctor, Carole J, et al.
Publicado: (2012)

Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection
por: Boelen, Ellen, et al.
Publicado: (2007)

Tyrosine Rotamer States in Beta Amyloid: Signatures of Aggregation and Fibrillation
por: Mancini, Onorio, et al.
Publicado: (2018)

Unbiased high-content screening reveals Aβ- and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer’s patients and high-pathology controls
por: Jiang, Hao, et al.
Publicado: (2021)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Soluble amyloid beta levels are elevated in the white matter of Alzheimer’s patients, independent of cortical plaque severity
por: Collins-Praino, Lyndsey E, et al.
Publicado: (2014)

Phosphorylation of amyloid beta (Aβ) peptides – A trigger for formation of toxic aggregates in Alzheimer's disease
por: Kumar, Sathish, et al.
Publicado: (2011)

Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease
por: Du, Hongtao, et al.
Publicado: (2023)

Magnetoelectric dissociation of Alzheimer’s β-amyloid aggregates
por: Jang, Jinhyeong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_le2svgon0s16u7o4dg1i13kr8m